{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:39:18Z","timestamp":1793367558886,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T00:00:00Z","timestamp":1607472000000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Biological therapies have improved the clinical course and quality of life of rheumatoid arthritis (RA) patients. Despite the availability and effectiveness of these treatments, some patients experience multiple failures to biologic disease-modifying antirheumatic drugs (bDMARDs), constituting a particular challenge to clinicians.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>This study aims to determine the percentage of rheumatoid arthritis (RA) patients who fail to respond to subsequent bDMARDs, describe their characteristics, and identify specific baseline and early features during the first bDMARD as possible predictors of consecutive multiple bDMARD failure.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a longitudinal study involving RA patients from the prospective biological cohort drawn from the La Paz University Hospital RA Registry (RA-Paz), starting a bDMARD during the years 2000 to 2019. Patients who presented insufficient response (due to primary or secondary inefficacy) to at least three bDMARDs or two bDMARDs with different mechanism of action were considered multi-refractory (<jats:italic>MR-patients<\/jats:italic>). Patients who achieved low disease activity or remission (by DAS-28) with the first bDMARD and maintained this over a follow-up period of at least 5\u2009years were considered non-refractory (<jats:italic>NR-patients<\/jats:italic>)<jats:italic>.<\/jats:italic><\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 41 out of 402 (10%) patients were MR-patients and 71 (18%) NR-patients. In the multivariate analysis, the presence of erosions, younger age, higher baseline DAS-28 and mostly achieving delta-DAS &lt;\u20091.2 after 6\u2009months of the first bDMARD (OR 11.12; 95% CI 3.34\u201326.82) were independently associated with being MR-patients to bDMARDs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In our cohort, 10% of patients with RA were observed to have multi-refractoriness to bDMARDs. This study supports the contention that younger patients with erosive disease and especially the early absence of clinical response to the first bDMARDs are predictors of multi-refractoriness to consecutive biologics. Hence, patients with these characteristics should be monitored more closely and may benefit from personalized treatments.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-020-02354-1","type":"journal-article","created":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T11:23:52Z","timestamp":1607513032000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Clinical predictors of multiple failure to biological therapy in patients with rheumatoid arthritis"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2200-0859","authenticated-orcid":false,"given":"Marta","family":"Novella-Navarro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chamaida","family":"Plasencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Tornero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Navarro-Comp\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 L.","family":"Cabrera-Alarc\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Peiteado-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Nu\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Monjo-Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Franco-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Villalba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Balsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,9]]},"reference":[{"key":"2354_CR1","doi-asserted-by":"publisher","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ, Burmester G, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655.","DOI":"10.1136\/annrheumdis-2019-216655"},{"key":"2354_CR2","first-page":"1","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68:1\u201326.","journal-title":"Arthritis Rheumatol"},{"key":"2354_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75:3\u201315.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2354_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/art.27227","volume":"62","author":"ML Hetland","year":"2010","unstructured":"Hetland ML, Christensen IJ, Tarp U, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010;62(1):22\u201332.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2354_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/art.22331","volume":"56","author":"KL Hyrich","year":"2007","unstructured":"Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ, British Society for Rheumatology Biologics Register. Outcomes after switching from one antitumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum. 2007;56(1):13\u201320.","journal-title":"Arthritis Rheum"},{"key":"2354_CR6","doi-asserted-by":"publisher","first-page":"170","DOI":"10.2174\/1381612820666140825123104","volume":"21","author":"I Gonz\u00e1lez-\u00c1lvaro","year":"2015","unstructured":"Gonz\u00e1lez-\u00c1lvaro I, Ortiz AM, Seoane IV, Garc\u00eda-Vicu\u00f1a R, Mart\u00ednez C, Gomariz RP. Biomarkers predicting a need for intensive treatment in patients with early arthritis. Curr Pharm Des. 2015;21:170\u201381.","journal-title":"Curr Pharm Des"},{"key":"2354_CR7","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/art.20159","volume":"50","author":"RN Maini","year":"2004","unstructured":"Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al. Sustained improvement over two years in physical function, structural damage, and sings and symptoms among patients with rheumatoid arthritis treated with infliximab and metothrexate. Arthritis Rheum. 2004;50:1051\u201365.","journal-title":"Arthritis Rheum"},{"key":"2354_CR8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jbspin.2013.04.005","volume":"81","author":"F Azteni","year":"2014","unstructured":"Azteni F, Bongiovanni S, Marchesoni A, Filippini M, Caporali R, Gorla R, et al. Predictors of response to anti-TNF therapy in RA patients with moderate or high DAS28 scores. Joint Bone Spine. 2014;81:37\u201340.","journal-title":"Joint Bone Spine"},{"key":"2354_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/1529-0131(200001)43:1<22::AID-ANR4>3.0.CO;2-9","volume":"43","author":"JJ Anderson","year":"2000","unstructured":"Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum. 2000;43:22\u20139.","journal-title":"Arthritis Rheum"},{"key":"2354_CR10","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1136\/annrheumdis-2018-213378","volume":"77","author":"L Kearsley-Fleet","year":"2018","unstructured":"Kearsley-Fleet L, Davies R, De Cock D, Watson KD, Lunt M, Buch MH, et al. Biologic refractory disease in rheumatoid arthritis: results from de British Society for Rheumatology Biologic Register for Rheumatoid Arthritis. Ann Rheum Dis. 2018;77:1405\u201312.","journal-title":"Ann Rheum Dis"},{"key":"2354_CR11","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.semarthrit.2019.02.004","volume":"49","author":"M B\u00e9c\u00e8de","year":"2019","unstructured":"B\u00e9c\u00e8de M, Alasti F, Gessl I, Haupt L, Kerschbaumer A, Landesmann U, et al. Risk profiling for a refractory course of rheumatoid arthritis. Seminars Arthritis Rheum. 2019;49:211\u20137.","journal-title":"Seminars Arthritis Rheum"},{"issue":"3","key":"2354_CR12","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s10067-018-4355-0","volume":"38","author":"A Mart\u00ednez-Feito","year":"2019","unstructured":"Mart\u00ednez-Feito A, Plasencia-Rodr\u00edguez C, Navarro-Comp\u00e1n V, Hernandez-Breijo B, Gonz\u00e1lez MA, Monjo I, et al. The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors. Clin Rheumatol. 2019;38(3):949\u201395.","journal-title":"Clin Rheumatol"},{"key":"2354_CR13","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315\u201324.","journal-title":"Arthritis Rheum"},{"key":"2354_CR14","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum. 2010;62:2569\u201381.","journal-title":"Arthritis Rheum"},{"key":"2354_CR15","first-page":"1135","volume":"57","author":"MJH De Hair","year":"2018","unstructured":"De Hair MJH, Jacobs JWG, Schoneveld JLM, Van Laar JM. Difficult-to treat rheumatoid arthritis: an area of unmet clinical need. Rheumatology. 2018;57:1135\u201344.","journal-title":"Rheumatology"},{"key":"2354_CR16","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1136\/annrheumdis-2017-212862","volume":"77","author":"MH Buch","year":"2018","unstructured":"Buch MH. Defining refractory rheumatoid arthritis. Ann Rheum Dis. 2018;77:966\u20139.","journal-title":"Ann Rheum Dis"},{"key":"2354_CR17","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1093\/rheumatology\/keu158","volume":"53","author":"EG Favalli","year":"2014","unstructured":"Favalli EG, Biggioggero M, Marchesoni A, Meroni PL. Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. Rheumatology. 2014;53:1664\u20138.","journal-title":"Rheumatology"},{"key":"2354_CR18","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1002\/art.22943","volume":"56","author":"D Aletaha","year":"2007","unstructured":"Aletaha D, Funovits J, Keystone EC, Smolen JS. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum. 2007;56:3226\u201335.","journal-title":"Arthritis Rheum"},{"key":"2354_CR19","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1136\/ard.2008.105064","volume":"69","author":"A Finckh","year":"2010","unstructured":"Finckh A, Ciurea A, Brulhart L, M\u00f6ller B, Walker UA, Courvoisier D, et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis. 2010;69:387\u201393.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"2354_CR20","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1093\/rheumatology\/kez518","volume":"59","author":"PDH Hamann","year":"2020","unstructured":"Hamann PDH, Pauling JD, McHugh N, Hyrich K, Shaddick G. Early responses to anti-TNF predicts long-term outcomes including sustained remission: an analysis of the BSRBR-RA. Rheumatologys. 2020;59(7):1709\u201314.","journal-title":"Rheumatologys"},{"issue":"3","key":"2354_CR21","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/art.21678","volume":"54","author":"JS Smolen","year":"2006","unstructured":"Smolen JS, Van Der Heide D, StClaire W, Emery P, Bathon JM, Keystone E, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum. 2006;54(3):702\u201310.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"2354_CR22","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1002\/art.40090","volume":"69","author":"JM Gwinnutt","year":"2017","unstructured":"Gwinnutt JM, Symmons DPM, MacGregor AJ, Chipping JR, Marshall T, Lunt M, et al. Twenty-year outcome and association between early treatment and mortality and disability in an inception cohort of patients with rheumatoid arthritis: results from the Norfolk arthritis register. Arthritis Rheumatol. 2017;69(8):1566\u201375.","journal-title":"Arthritis Rheumatol"},{"key":"2354_CR23","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1136\/annrheumdis-2018-213687","volume":"77","author":"NMT Roodenrijs","year":"2018","unstructured":"Roodenrijs NMT, de Hair MJH, Van der Goes MC, Jacobs JWG, Welsing PMJ, van der Heijde D, et al. Characteristics of difficult-to treat rheumatoid arthritis: a result of an international survey. Ann Rheum Dis. 2018;77:1705\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"2354_CR24","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s40265-020-01309-9","volume":"80","author":"AR Melville","year":"2020","unstructured":"Melville AR, Kearsley-Fleet L, Buch MH, Hyrich KL. Understanding refractory rheumatoid arthritis: implications for a therapeutic approach. Drugs. 2020;80(9):849\u201357.","journal-title":"Drugs."},{"issue":"1","key":"2354_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/acr.23815","volume":"72","author":"HB Hammer","year":"2020","unstructured":"Hammer HB, Michelsen B, Provan SA, Sexton J, Lampa J, Uhlig T, et al. Tender joint count and inflammatory activity in patients with established rheumatoid arthritis: results from a longitudinal study. Arthritis Care Res (Hoboken). 2020;72(1):27\u201335.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"2354_CR26","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/acr.22107","volume":"66","author":"LE Kristensen","year":"2014","unstructured":"Kristensen LE, Bliddal H, Christensen R, Karlsson JA, G\u00fclfe A, Saxne T, et al. In swollen to tender joint count ratio a new and useful clinical marker for biologic drug response in rheumatoid arthritis? Results from a Swedish cohort. Arthritis Care Res (Hoboken). 2014;66(2):173\u20139.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2354_CR27","doi-asserted-by":"publisher","first-page":"R221","DOI":"10.1186\/ar4421","volume":"15","author":"E Balogh","year":"2013","unstructured":"Balogh E, Madruga-Dias J, Orr C, Mullan R, Harty L, Firtgerald O, et al. Comparison of remission criteria in a tumour necrosis factor inhibitor treated rheumatoid arthritis longitudinal cohort: patient global health is a confounder. Arthritis Res Ther. 2013;15:R221.","journal-title":"Arthritis Res Ther"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02354-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-020-02354-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02354-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T11:58:17Z","timestamp":1607515097000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-020-02354-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2354"],"URL":"https:\/\/doi.org\/10.1186\/s13075-020-02354-1","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"27 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the local medical ethics committee (PI-1155). And consent information was obtained from all participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No competing interests applicable regarding this manuscript, but A.B. has received grant\/research support and fees for consultancies or as a speaker from Abbvie, Amgen, Pfizer, Novartis, BMS, Nordic, Sanofi, Sandoz, Lilly, UCB, and Roche. C.P.R. has received speaking fees or funding for research projects from Pfizer, Lilly, Novartis, Abbvie, and Roche. V.N.C. has received research grants from Abbvie, Merck, Novartis, Pfizer, and ASAS and consulting fees from Abbvie, Lilly, Novartis, Pfizer, and UCB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"284"}}